Overview

What is the Scottish Diabetes Research Network Type 1 Bioresource?

The Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) is a large and comprehensive collection of biosamples and electronic health care record data from 6,127 adults in Scotland with type 1 diabetes. We are a research collaboration involving researchers, clinicians and people with diabetes. The SDRNT1BIO is a unique resource with extensive retrospective and prospective capture of a wide range of health data, coupled with available biosamples, from a cohort that is representative of the national adult population with type 1 diabetes. 

It was established during 2010-13 and involved adults with type 1 diabetes aged 16 years and older, across 12 Scottish NHS Health Boards. Participants volunteered to be part of this research when they were asked during their diabetic review visits at hospital and GP clinics. 

Participants provided baseline blood and urine samples to be stored for use in research projects, along with baseline physical measurements and completed a lifestyle and disease management questionnaire. They also agreed for researchers to have access to their electronic health care records over time. Many participants also agreed to have any spare blood from follow-up samples taken during routine clinic visits stored for future research. 

For more information on the study organisation or to contact the study team, please use the links below:

 

Funding

Image

The SDRNT1BIO was established with joint funding from the Scottish Chief Scientist Office (CSO; ref: ETM/47) and Diabetes UK (ref: 10/000410).

Research using data and resources sourced by the SDRNT1BIO has been funded by the Juvenile Diabetes Research Foundation (JDRF), Diabetes UK and the Medical Research Council.

SDRNT1BIO was established with joint funding from the Scottish Chief Scientist Office (CSO) and DiabetesUK. SDRNT1BIO research activity has been funded by Diabetes UK, Medical Research Council (UKRI) and Juvenile Diabetes Research Foundation (JDRF; now Breakthrough T1D)